PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...

ILiAD Biotechnologies leads this week's round-up of new private financings in the biopharma sector, with a $115 million Series B investment that will be used to test a new type of whooping cough ...

The pharmaceutical industry has long positioned itself as patient- or customer-focused. Our vision, mission and values statements are full of purpose-driven language, ethical intent, and references to ...

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

EVERSANA, a leading provider of commercialisation services to the global life sciences industry, has named Monica Avram as ...

Private equity firm expands healthcare focus. Inflexion, a leading European mid-market private equity firm, appointed John ...

According to Invest Europe, the challenge facing the European life sciences sector is clear - Europe currently accounts for ...

In its main clinical trial, mRNA-1010 was shown to be 26.6% more effective than the comparator flu shot in adults aged 50 ...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas. Built from ...

Zydus Lifesciences has reached a settlement agreement with Astellas in a patent dispute involving overactive bladder therapy Myrbetriq, which will allow its generic to remain on sale in the US.

Sanofi has announced a change of leadership, with former Merck KGaA chief executive Belén Garijo taking the helm of the French group from Paul Hudson, whose contract will not be renewed.

Madrigal Pharma was the first drugmaker to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to ...